JP2010519003A - 神経障害の治療のための電気刺激装置と方法 - Google Patents
神経障害の治療のための電気刺激装置と方法 Download PDFInfo
- Publication number
- JP2010519003A JP2010519003A JP2009551717A JP2009551717A JP2010519003A JP 2010519003 A JP2010519003 A JP 2010519003A JP 2009551717 A JP2009551717 A JP 2009551717A JP 2009551717 A JP2009551717 A JP 2009551717A JP 2010519003 A JP2010519003 A JP 2010519003A
- Authority
- JP
- Japan
- Prior art keywords
- channel
- patient
- electrode
- stimulate
- electrical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000638 stimulation Effects 0.000 title claims abstract description 328
- 238000000034 method Methods 0.000 title claims abstract description 155
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 42
- 238000011282 treatment Methods 0.000 title abstract description 128
- 208000025966 Neurological disease Diseases 0.000 title abstract description 22
- 230000033001 locomotion Effects 0.000 claims abstract description 104
- 230000002232 neuromuscular Effects 0.000 claims abstract description 93
- 210000000746 body region Anatomy 0.000 claims abstract description 31
- 230000002093 peripheral effect Effects 0.000 claims abstract description 24
- 210000003205 muscle Anatomy 0.000 claims description 286
- 210000001519 tissue Anatomy 0.000 claims description 173
- 230000003238 somatosensory effect Effects 0.000 claims description 61
- 210000003141 lower extremity Anatomy 0.000 claims description 51
- 210000003625 skull Anatomy 0.000 claims description 35
- 210000002414 leg Anatomy 0.000 claims description 33
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 31
- 210000000707 wrist Anatomy 0.000 claims description 30
- 210000003811 finger Anatomy 0.000 claims description 29
- 201000001119 neuropathy Diseases 0.000 claims description 29
- 230000007823 neuropathy Effects 0.000 claims description 29
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 26
- 210000002683 foot Anatomy 0.000 claims description 20
- 210000000245 forearm Anatomy 0.000 claims description 20
- 230000002051 biphasic effect Effects 0.000 claims description 18
- 210000002442 prefrontal cortex Anatomy 0.000 claims description 18
- 210000000115 thoracic cavity Anatomy 0.000 claims description 17
- 210000001624 hip Anatomy 0.000 claims description 16
- 210000003813 thumb Anatomy 0.000 claims description 16
- 210000001097 facial muscle Anatomy 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 210000003423 ankle Anatomy 0.000 claims description 13
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 13
- 210000003489 abdominal muscle Anatomy 0.000 claims description 12
- 210000000038 chest Anatomy 0.000 claims description 12
- 210000003314 quadriceps muscle Anatomy 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 10
- 210000000852 deltoid muscle Anatomy 0.000 claims description 10
- 210000001061 forehead Anatomy 0.000 claims description 10
- 230000001537 neural effect Effects 0.000 claims description 9
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims description 8
- 230000001351 cycling effect Effects 0.000 claims description 8
- 210000002027 skeletal muscle Anatomy 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 210000002303 tibia Anatomy 0.000 claims description 6
- 210000000689 upper leg Anatomy 0.000 claims description 6
- 201000002154 Pterygium Diseases 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 230000001815 facial effect Effects 0.000 claims description 5
- 210000001352 masseter muscle Anatomy 0.000 claims description 5
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 5
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims description 4
- 230000003187 abdominal effect Effects 0.000 claims description 4
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 4
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 210000004247 hand Anatomy 0.000 claims description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims description 4
- 210000003800 pharynx Anatomy 0.000 claims description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 4
- 210000000617 arm Anatomy 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 210000002976 pectoralis muscle Anatomy 0.000 claims description 3
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims description 3
- 230000005611 electricity Effects 0.000 claims description 2
- 210000001872 metatarsal bone Anatomy 0.000 claims description 2
- 210000004237 neck muscle Anatomy 0.000 claims description 2
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims 11
- 230000003042 antagnostic effect Effects 0.000 claims 4
- 230000002902 bimodal effect Effects 0.000 claims 2
- 229940123468 Transferase inhibitor Drugs 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000004932 little finger Anatomy 0.000 claims 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 abstract description 93
- 108091006146 Channels Proteins 0.000 description 181
- 230000004936 stimulating effect Effects 0.000 description 28
- 210000000337 motor cortex Anatomy 0.000 description 26
- 210000001364 upper extremity Anatomy 0.000 description 26
- 238000010586 diagram Methods 0.000 description 20
- 210000003127 knee Anatomy 0.000 description 18
- 210000004092 somatosensory cortex Anatomy 0.000 description 18
- 230000002457 bidirectional effect Effects 0.000 description 15
- 210000005036 nerve Anatomy 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 229940076279 serotonin Drugs 0.000 description 12
- 230000007935 neutral effect Effects 0.000 description 11
- 208000006011 Stroke Diseases 0.000 description 10
- 108010092674 Enkephalins Proteins 0.000 description 9
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 108010049140 Endorphins Proteins 0.000 description 8
- 102000009025 Endorphins Human genes 0.000 description 8
- 230000002146 bilateral effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000010304 firing Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001953 sensory effect Effects 0.000 description 7
- 210000003371 toe Anatomy 0.000 description 7
- 210000003128 head Anatomy 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 230000009747 swallowing Effects 0.000 description 6
- 230000009184 walking Effects 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 5
- 230000005021 gait Effects 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000002747 voluntary effect Effects 0.000 description 5
- 108010065372 Dynorphins Proteins 0.000 description 4
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 4
- 210000002310 elbow joint Anatomy 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 210000004761 scalp Anatomy 0.000 description 4
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 4
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 4
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000008238 Muscle Spasticity Diseases 0.000 description 3
- 208000029578 Muscle disease Diseases 0.000 description 3
- 208000010316 Myotonia congenita Diseases 0.000 description 3
- 108010075750 P-Type Calcium Channels Proteins 0.000 description 3
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 3
- 206010044625 Trichorrhexis Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 229960001058 bupropion Drugs 0.000 description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000001847 jaw Anatomy 0.000 description 3
- 210000004705 lumbosacral region Anatomy 0.000 description 3
- 210000004373 mandible Anatomy 0.000 description 3
- 239000003697 methyltransferase inhibitor Substances 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 210000000715 neuromuscular junction Anatomy 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 208000018198 spasticity Diseases 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000002320 spinal muscular atrophy Diseases 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 208000029323 Congenital myotonia Diseases 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 206010060860 Neurological symptom Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102100024622 Proenkephalin-B Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001055 chewing effect Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229940052760 dopamine agonists Drugs 0.000 description 2
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 230000005714 functional activity Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- RERZNCLIYCABFS-UHFFFAOYSA-N harmaline Chemical compound C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004090 maprotiline Drugs 0.000 description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001617 median nerve Anatomy 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 208000029308 periodic paralysis Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- -1 pyrivezil Chemical compound 0.000 description 2
- 229960003770 reboxetine Drugs 0.000 description 2
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- FBOUYBDGKBSUES-VXKWHMMOSA-N solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 2
- 229960003855 solifenacin Drugs 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 238000002646 transcutaneous electrical nerve stimulation Methods 0.000 description 2
- 229960001032 trihexyphenidyl Drugs 0.000 description 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 2
- 210000000658 ulnar nerve Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N 2-amino-4-methylselanyl-butanoic acid Chemical compound C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000015374 Central core disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229940123379 Methyltransferase inhibitor Drugs 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241001503699 Muscovy duck parvovirus Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 description 1
- 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 description 1
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000004228 Riboflavin-5'-Phosphate Substances 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000002659 acromion Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000006960 adult spinal muscular atrophy Diseases 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229960000451 ambenonium Drugs 0.000 description 1
- OMHBPUNFVFNHJK-UHFFFAOYSA-P ambenonium Chemical compound C=1C=CC=C(Cl)C=1C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](CC)(CC)CC1=CC=CC=C1Cl OMHBPUNFVFNHJK-UHFFFAOYSA-P 0.000 description 1
- 229960000959 amineptine Drugs 0.000 description 1
- ONNOFKFOZAJDHT-UHFFFAOYSA-N amineptine Chemical compound C1CC2=CC=CC=C2C(NCCCCCCC(=O)O)C2=CC=CC=C21 ONNOFKFOZAJDHT-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 229960001862 atracurium Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000007303 central core myopathy Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 dicycloverine Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004428 doxacurium Drugs 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 229960003748 edrophonium Drugs 0.000 description 1
- 229940098766 effexor Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- 229960000855 flavoxate Drugs 0.000 description 1
- SPIUTQOUKAMGCX-UHFFFAOYSA-N flavoxate Chemical compound C1=CC=C2C(=O)C(C)=C(C=3C=CC=CC=3)OC2=C1C(=O)OCCN1CCCCC1 SPIUTQOUKAMGCX-UHFFFAOYSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 229960002589 iproclozide Drugs 0.000 description 1
- GGECDTUJZOXAAR-UHFFFAOYSA-N iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- CVQFAMQDTWVJSV-BAXNFHPCSA-N lisuride maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 CVQFAMQDTWVJSV-BAXNFHPCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 238000010077 mastication Methods 0.000 description 1
- GBLRQXKSCRCLBZ-IYQFLEDGSA-N meso-doxacurium Chemical compound COC1=C(OC)C(OC)=CC(C[C@@H]2[N@@+](CCC3=C2C(=C(OC)C(OC)=C3)OC)(C)CCCOC(=O)CCC(=O)OCCC[N@@+]2(C)[C@@H](C3=C(OC)C(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=C(OC)C=2)=C1 GBLRQXKSCRCLBZ-IYQFLEDGSA-N 0.000 description 1
- 210000000236 metacarpal bone Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- SYHGEUNFJIGTRX-UHFFFAOYSA-N methylenedioxypyrovalerone Chemical compound C=1C=C2OCOC2=CC=1C(=O)C(CCC)N1CCCC1 SYHGEUNFJIGTRX-UHFFFAOYSA-N 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- 230000005404 monopole Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000013315 neuromuscular junction disease Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 208000029278 non-syndromic brachydactyly of fingers Diseases 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 229960003209 phenmetrazine Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
- 229960004633 pirenzepine Drugs 0.000 description 1
- 210000001698 popliteal fossa Anatomy 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000000976 primary motor cortex Anatomy 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 210000002176 pterygoid muscle Anatomy 0.000 description 1
- 229960002290 pyridostigmine Drugs 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 210000002979 radial nerve Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 229960000245 rasagiline Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 229960003179 rotigotine Drugs 0.000 description 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 210000002972 tibial nerve Anatomy 0.000 description 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 1
- 229940110309 tiotropium Drugs 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 229960001844 tubocurarine Drugs 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
- 208000032521 type II spinal muscular atrophy Diseases 0.000 description 1
- 208000005606 type IV spinal muscular atrophy Diseases 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 229950007136 vanoxerine Drugs 0.000 description 1
- NAUWTFJOPJWYOT-UHFFFAOYSA-N vanoxerine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)OCCN1CCN(CCCC=2C=CC=CC=2)CC1 NAUWTFJOPJWYOT-UHFFFAOYSA-N 0.000 description 1
- 229960003819 vecuronium Drugs 0.000 description 1
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 235000020942 vitamer Nutrition 0.000 description 1
- 239000011608 vitamer Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- QUSLQENMLDRCTO-YJNKXOJESA-N win 35428 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(F)C=C1 QUSLQENMLDRCTO-YJNKXOJESA-N 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/323—Interference currents, i.e. treatment by several currents summed in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0452—Specially adapted for transcutaneous muscle stimulation [TMS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0456—Specially adapted for transcutaneous electrical nerve stimulation [TENS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0492—Patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36003—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of motor muscles, e.g. for walking assistance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
- A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/36128—Control systems
- A61N1/36146—Control systems specified by the stimulation parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0476—Array electrodes (including any electrode arrangement with more than one electrode for at least one of the polarities)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0529—Electrodes for brain stimulation
- A61N1/0531—Brain cortex electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/0526—Head electrodes
- A61N1/0548—Oral electrodes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Disabilities (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Social Psychology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/711,285 US7949403B2 (en) | 2007-02-27 | 2007-02-27 | Electrical stimulation device and method for the treatment of neurological disorders |
| PCT/US2008/002601 WO2008106174A1 (en) | 2007-02-27 | 2008-02-27 | Electrical stimulation device and method for the treatment of neurological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010519003A true JP2010519003A (ja) | 2010-06-03 |
| JP2010519003A5 JP2010519003A5 (enExample) | 2011-04-14 |
Family
ID=39716801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551717A Pending JP2010519003A (ja) | 2007-02-27 | 2008-02-27 | 神経障害の治療のための電気刺激装置と方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US7949403B2 (enExample) |
| EP (1) | EP2114516A4 (enExample) |
| JP (1) | JP2010519003A (enExample) |
| WO (1) | WO2008106174A1 (enExample) |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013517049A (ja) * | 2010-01-15 | 2013-05-16 | チク,エルエルシー | 足筋のプログラム可能電気刺激 |
| JP2013525017A (ja) * | 2010-04-28 | 2013-06-20 | メーガン メディカル,インコーポレーテッド | 感覚神経を刺激するシステム及び方法 |
| JP2013215514A (ja) * | 2012-04-12 | 2013-10-24 | Nihon Medix | 電気的刺激装置およびその電極装置 |
| JP2014188015A (ja) * | 2013-03-26 | 2014-10-06 | Kensuke Yamakawa | 電気的刺激装置 |
| JP2015525579A (ja) * | 2012-06-26 | 2015-09-07 | マインドテック・インコーポレイテッド | 機能的電気刺激治療のための方法 |
| JP2017080490A (ja) * | 2011-03-10 | 2017-05-18 | エレクトロコア リミテッド ライアビリティ カンパニー | 非侵襲的容量性電気刺激のためのデバイスおよび方法、ならびに患者の頸部の迷走神経刺激のためのそれらの使用 |
| JP2017525495A (ja) * | 2014-08-26 | 2017-09-07 | アヴェント インコーポレイテッド | 選択的神経線維ブロック方法及びシステム |
| JP2018526142A (ja) * | 2015-09-08 | 2018-09-13 | ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University | 経皮直流電流ブロックによる神経伝導変更システム及び方法 |
| JP2018183481A (ja) * | 2017-04-27 | 2018-11-22 | 株式会社 Mtg | 筋肉電気刺激装置 |
| WO2019107768A1 (ko) * | 2017-11-30 | 2019-06-06 | 주식회사 싸이버메딕 | 실시간 뇌 활성도 변화에 따른 모니터링과 중추 및 말초 신경 복합자극을 통한 뇌신경 조절장치 |
| JP2019103655A (ja) * | 2017-12-13 | 2019-06-27 | 日本電信電話株式会社 | 筋緊張制御装置、筋緊張制御方法およびプログラム |
| KR20190128129A (ko) * | 2017-11-30 | 2019-11-15 | 주식회사 싸이버메딕 | 실시간 뇌 활성도 변화에 따른 모니터링과 중추 및 말초 신경 복합자극을 통한 뇌신경 조절장치 |
| WO2021107649A3 (ko) * | 2019-11-29 | 2021-07-15 | (주)와이브레인 | 환자의 신경에 전기적인 자극을 가하여 신경을 조절하는 장치 및 그 방법 |
| JP2022008274A (ja) * | 2016-03-24 | 2022-01-13 | ヴィヴォニクス・インコーポレーテッド | ヒト被験者の前庭活動を抑制するためのシステムおよび方法 |
| JP2022168040A (ja) * | 2013-01-21 | 2022-11-04 | カラ ヘルス,インコーポレイテッド | 振戦を抑制する装置及び方法 |
| JP2023083291A (ja) * | 2018-10-15 | 2023-06-15 | ノボキュア ゲーエムベーハー | 脳全体にわたる高均一性での腫瘍治療電場(tt電場)の発生 |
| WO2024071669A1 (ko) * | 2022-09-29 | 2024-04-04 | 서울대학교산학협력단 | 뇌심부 자극 장치 및 이의 제어 방법 |
| JP2024515260A (ja) * | 2021-04-08 | 2024-04-08 | ノボキュア ゲーエムベーハー | 交流電場を用いて神経変性障害を処置する方法 |
Families Citing this family (230)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8346367B2 (en) * | 2002-09-11 | 2013-01-01 | Meagan Medical, Inc. | Apparatus and method for stabilizing, improving mobility, and controlling cartilage matrix degradation of weight-bearing articular joints |
| US8060210B1 (en) | 2002-09-11 | 2011-11-15 | International Rehabilitative Sciences, Inc. | Methods for improving mobility and controlling cartilage matrix degradation of weight-bearing articular joints |
| US9433797B2 (en) | 2003-12-05 | 2016-09-06 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurodegenerative conditions |
| US10350428B2 (en) | 2014-11-04 | 2019-07-16 | Endonovo Therapetics, Inc. | Method and apparatus for electromagnetic treatment of living systems |
| US9415233B2 (en) | 2003-12-05 | 2016-08-16 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological pain |
| US8961385B2 (en) | 2003-12-05 | 2015-02-24 | Ivivi Health Sciences, Llc | Devices and method for treatment of degenerative joint diseases with electromagnetic fields |
| US9440089B2 (en) | 2003-12-05 | 2016-09-13 | Rio Grande Neurosciences, Inc. | Apparatus and method for electromagnetic treatment of neurological injury or condition caused by a stroke |
| US9427598B2 (en) * | 2010-10-01 | 2016-08-30 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic treatment of head, cerebral and neural injury in animals and humans |
| US9656096B2 (en) | 2003-12-05 | 2017-05-23 | Rio Grande Neurosciences, Inc. | Method and apparatus for electromagnetic enhancement of biochemical signaling pathways for therapeutics and prophylaxis in plants, animals and humans |
| US20070073354A1 (en) | 2005-09-26 | 2007-03-29 | Knudson Mark B | Neural blocking therapy |
| US9174066B2 (en) * | 2009-03-20 | 2015-11-03 | ElectroCore, LLC | Devices and methods for non-invasive capacitive electrical stimulation and their use for vagus nerve stimulation on the neck of a patient |
| US8932195B2 (en) * | 2006-06-30 | 2015-01-13 | Research Foundation Of The City University Of New York | Process and apparatus for improving neuronal performance |
| US7949403B2 (en) | 2007-02-27 | 2011-05-24 | Accelerated Care Plus Corp. | Electrical stimulation device and method for the treatment of neurological disorders |
| US20090204173A1 (en) | 2007-11-05 | 2009-08-13 | Zi-Ping Fang | Multi-Frequency Neural Treatments and Associated Systems and Methods |
| US8849407B1 (en) | 2008-01-04 | 2014-09-30 | Yuri P. Danilov | Non-invasive neuromodulation (NINM) for rehabilitation of brain function |
| WO2009122485A1 (ja) | 2008-03-31 | 2009-10-08 | 岡山県 | 生体計測装置及び生体刺激装置 |
| EP3173125B1 (en) | 2008-07-30 | 2019-03-27 | Ecole Polytechnique Fédérale de Lausanne | Apparatus for optimized stimulation of a neurological target |
| US8265761B2 (en) * | 2008-08-18 | 2012-09-11 | David R Siever | Cranial-electro stimulator |
| EP2344239B1 (en) * | 2008-09-19 | 2019-11-06 | Terry William Burton Moore | Device for reducing muscle tension through electrical manipulation |
| US8255057B2 (en) | 2009-01-29 | 2012-08-28 | Nevro Corporation | Systems and methods for producing asynchronous neural responses to treat pain and/or other patient conditions |
| CA2743575C (en) | 2008-11-12 | 2017-01-31 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device |
| BRPI0918700B8 (pt) * | 2008-12-30 | 2021-06-22 | Univ City New York Res Found | conjuntos de eletrodo e aparelhos para a estimulação neurocraniana |
| US8080584B2 (en) * | 2009-01-23 | 2011-12-20 | Teva Pharmaceuticals Industries, Ltd. | Delayed release rasagiline citrate formulation |
| US20190240486A1 (en) * | 2009-03-20 | 2019-08-08 | Electrocore, Inc. | Non-invasive treatment of neurodegenerative diseases |
| US9561366B2 (en) * | 2009-03-27 | 2017-02-07 | Medtronic, Inc. | Conditional electrical stimulation |
| EP2419172A4 (en) * | 2009-04-13 | 2014-03-12 | Univ City New York Res Found | CRANIAL STIMULATION |
| EP4257178A3 (en) | 2009-04-22 | 2023-10-25 | Nevro Corporation | Spinal cord modulation systems for inducing paresthetic and anesthetic effects |
| DE202010018211U1 (de) | 2009-04-22 | 2014-09-29 | Nevro Corporation | Selektive Hochfrequenzrückenmarksmodulation zur Schmerzhemmung mit weniger Nebenwirkung, sowie zugehörige Systeme |
| JP5423957B2 (ja) * | 2009-07-07 | 2014-02-19 | 株式会社マルタカテクノ | 電子治療器 |
| WO2011003709A1 (en) * | 2009-07-10 | 2011-01-13 | University College Dublin, National University Of Ireland, Dublin | Method and apparatus for stimulating the lower back and abdominal muscles |
| US8498710B2 (en) | 2009-07-28 | 2013-07-30 | Nevro Corporation | Linked area parameter adjustment for spinal cord stimulation and associated systems and methods |
| EP2473229B1 (en) | 2009-09-03 | 2015-08-05 | Murdoch Childrens Research Institute | Transcutaneous stimulation system |
| EP2485799A4 (en) * | 2009-10-05 | 2013-05-15 | Univ California | EXTRACRANIAL IMPLANTABLE DEVICES, SYSTEMS AND METHOD FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES |
| US9008781B2 (en) | 2009-10-22 | 2015-04-14 | The Research Foundation Of The City University Of New York | Method and system for treatment of mobility dysfunction |
| US20130053922A1 (en) * | 2009-10-22 | 2013-02-28 | Zaghloul Ahmed | Dipole electrical stimulation employing direct current for recovery from spinal cord injury |
| EP2506920B1 (en) | 2009-12-01 | 2016-07-13 | Ecole Polytechnique Fédérale de Lausanne | Microfabricated surface neurostimulation device and method of making the same |
| SE534365C2 (sv) * | 2010-04-27 | 2011-07-26 | Inerventions Ab | System och klädesplagg för avslappning av en spastisk muskel |
| WO2011082071A1 (en) * | 2009-12-30 | 2011-07-07 | Boston Scientific Neuromodulation Corporation | System for independently operating multiple neurostimulation channels |
| EP2550060B1 (en) * | 2010-03-22 | 2019-03-13 | Research Foundation Of The City University Of New York | Charge-enhanced neural electric stimulation system |
| CN102905757B (zh) * | 2010-03-22 | 2016-02-17 | 纽约城市大学研究基金会 | 电荷增强神经电刺激系统 |
| JP5927176B2 (ja) | 2010-04-01 | 2016-06-01 | エコーレ ポリテクニーク フェデラーレ デ ローザンヌ (イーピーエフエル) | 神経組織と相互作用するためのデバイス、ならびにそれを作製および使用する方法 |
| WO2012047737A2 (en) | 2010-09-29 | 2012-04-12 | Articulate Labs, Inc. | Orthotic support and stimulus systems and methods |
| US9821159B2 (en) | 2010-11-16 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Stimulation devices and methods |
| JP2013542838A (ja) | 2010-11-16 | 2013-11-28 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ドライアイを治療するためのシステムおよび方法 |
| WO2012075198A2 (en) | 2010-11-30 | 2012-06-07 | Nevro Corporation | Extended pain relief via high frequency spinal cord modulation, and associated systems and methods |
| WO2012087530A1 (en) * | 2010-12-20 | 2012-06-28 | The University Of North Carolina Greensboro | Method and system of stimulation of nerve tissue with a sequence of spatially distributed resonant sub-threshold electrical stimuli |
| EP4201475A1 (en) | 2011-01-03 | 2023-06-28 | The Regents of the University of California | High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury |
| CN103608067A (zh) | 2011-01-21 | 2014-02-26 | 加利福尼亚理工学院 | 脊髓刺激法的聚对二甲苯基微电极阵列植入 |
| RU2609459C2 (ru) | 2011-03-02 | 2017-02-01 | Мердок Чилдренз Рисерч Инститьют | Способ и система чрескожной стимуляции |
| AU2012230699A1 (en) | 2011-03-24 | 2013-05-23 | California Institute Of Technology | Neurostimulator |
| WO2012154633A1 (en) * | 2011-05-06 | 2012-11-15 | Articulate Labs, Inc. | Joint rehabilitation apparatus and technique |
| EP2747636B1 (en) * | 2011-08-25 | 2019-03-20 | Insomnisolv, LLC | System for the treatment of insomnia |
| WO2013036880A1 (en) | 2011-09-08 | 2013-03-14 | Thacker James R | Selective high frequency spinal cord modulation for inhibiting pain, including cephalic and/or total body pain with reduced side effects, and associated systems and methods |
| US9265927B2 (en) * | 2011-09-09 | 2016-02-23 | Astora Women's Health, Llc | Tibial nerve stimulation device |
| US10092750B2 (en) | 2011-11-11 | 2018-10-09 | Neuroenabling Technologies, Inc. | Transcutaneous neuromodulation system and methods of using same |
| US9415218B2 (en) | 2011-11-11 | 2016-08-16 | The Regents Of The University Of California | Transcutaneous spinal cord stimulation: noninvasive tool for activation of locomotor circuitry |
| US9393409B2 (en) | 2011-11-11 | 2016-07-19 | Neuroenabling Technologies, Inc. | Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function |
| EP2802378A4 (en) * | 2012-01-13 | 2015-04-01 | Modular Therapeutx Llc | PORTABLE TRANSCUTANEOUS NEUROSTIMULATION APPARATUS AND METHOD OF USE |
| US8972016B2 (en) | 2012-01-13 | 2015-03-03 | Modular Therapeutx, Llc | Portable TENS apparatus and method of use thereof |
| US9764133B2 (en) | 2012-01-13 | 2017-09-19 | Modular Therapeutx, Llc | Portable TENS apparatus and method of use thereof |
| US8676331B2 (en) | 2012-04-02 | 2014-03-18 | Nevro Corporation | Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection |
| US10195434B2 (en) | 2012-06-15 | 2019-02-05 | Case Western Reserve University | Treatment of pain using electrical nerve conduction block |
| CA2876297C (en) | 2012-06-15 | 2019-02-26 | Case Western Reserve University | Therapy delivery devices and methods for non-damaging neural tissue conduction block |
| US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
| US11877860B2 (en) * | 2012-11-06 | 2024-01-23 | Nuvasive, Inc. | Systems and methods for performing neurophysiologic monitoring during spine surgery |
| US8974365B2 (en) * | 2012-11-25 | 2015-03-10 | Steven Richard Devore Best | Treatment of thalamocortical dysrhythmia |
| US10537703B2 (en) | 2012-11-26 | 2020-01-21 | Thync Global, Inc. | Systems and methods for transdermal electrical stimulation to improve sleep |
| US9440070B2 (en) | 2012-11-26 | 2016-09-13 | Thyne Global, Inc. | Wearable transdermal electrical stimulation devices and methods of using them |
| US10814131B2 (en) | 2012-11-26 | 2020-10-27 | Thync Global, Inc. | Apparatuses and methods for neuromodulation |
| CN103830841B (zh) | 2012-11-26 | 2018-04-06 | 赛威医疗公司 | 可穿戴的经皮肤的电刺激设备及其使用方法 |
| US9014811B2 (en) | 2013-06-29 | 2015-04-21 | Thync, Inc. | Transdermal electrical stimulation methods for modifying or inducing cognitive state |
| US9399126B2 (en) | 2014-02-27 | 2016-07-26 | Thync Global, Inc. | Methods for user control of neurostimulation to modify a cognitive state |
| US8874220B2 (en) * | 2012-12-13 | 2014-10-28 | Nuraleve Inc. | Neurostimulation system, device, and method |
| US20140194949A1 (en) * | 2013-01-04 | 2014-07-10 | Brian D. Wichner | Multiplex Electrodes for Applying Transcutaneous Interferential Current |
| US12453853B2 (en) | 2013-01-21 | 2025-10-28 | Cala Health, Inc. | Multi-modal stimulation for treating tremor |
| US9517339B2 (en) * | 2013-02-20 | 2016-12-13 | Indiana University Research And Technology Corporation | Method and system for training an individual |
| EP2964315B1 (en) * | 2013-03-07 | 2018-08-29 | Research Foundation Of The City University Of New York | System for treatment of neuromotor dysfunction |
| AU2014228794B2 (en) | 2013-03-15 | 2019-04-18 | The Regents Of The University Of California | Multi-site transcutaneous electrical stimulation of the spinal cord for facilitation of locomotion |
| AU2014253754C1 (en) | 2013-04-19 | 2015-07-30 | Oculeve, Inc. | Nasal stimulation devices and methods |
| US20150238764A1 (en) | 2013-05-10 | 2015-08-27 | Case Western Reserve University | Systems and methods for preventing noise in an electric waveform for neural stimulation, block, or sensing |
| US9895539B1 (en) | 2013-06-10 | 2018-02-20 | Nevro Corp. | Methods and systems for disease treatment using electrical stimulation |
| US10293161B2 (en) | 2013-06-29 | 2019-05-21 | Thync Global, Inc. | Apparatuses and methods for transdermal electrical stimulation of nerves to modify or induce a cognitive state |
| CN107715258B (zh) | 2013-09-17 | 2021-03-02 | 诺维图姆医疗科技有限公司 | 静脉电刺激装置和方法 |
| EP3049148B1 (en) | 2013-09-27 | 2020-05-20 | The Regents Of The University Of California | Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects |
| US9375569B2 (en) | 2013-10-03 | 2016-06-28 | Ensilver Canada | Controller unit for a functional electrical stimulation (FES) orthotic system |
| US9333345B2 (en) | 2013-10-03 | 2016-05-10 | Ensilver Canada | Electrical stimulation for a functional electrical stimulation system |
| US9375570B2 (en) | 2013-10-03 | 2016-06-28 | Ensilver Canada | Sensor unit for a functional electrical stimulation (FES) orthotic system |
| CA2926834A1 (en) * | 2013-10-11 | 2015-04-16 | Gi Therapies Pty Ltd | Stimulation device and method for transcutaneous electrical stimulation |
| US10149978B1 (en) | 2013-11-07 | 2018-12-11 | Nevro Corp. | Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods |
| US20150217120A1 (en) | 2014-01-13 | 2015-08-06 | Mandheerej Nandra | Neuromodulation systems and methods of using same |
| US9186505B2 (en) | 2014-02-21 | 2015-11-17 | Novo HB, LLC | Transcranial electrostimulation device and method |
| CN111298285A (zh) | 2014-02-25 | 2020-06-19 | 奥库利维公司 | 用于鼻泪刺激的聚合物制剂 |
| US9320913B2 (en) | 2014-04-16 | 2016-04-26 | Rio Grande Neurosciences, Inc. | Two-part pulsed electromagnetic field applicator for application of therapeutic energy |
| US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
| CN110585588A (zh) | 2014-05-16 | 2019-12-20 | 阿莱瓦神经治疗股份有限公司 | 可植入式微电极装置 |
| HK1250673A1 (zh) | 2014-05-17 | 2019-01-11 | 赛威医疗公司 | 使用经皮神经刺激来应用总体波形的方法和装置 |
| US9393401B2 (en) | 2014-05-25 | 2016-07-19 | Thync Global, Inc. | Wearable transdermal neurostimulator having cantilevered attachment |
| US9333334B2 (en) | 2014-05-25 | 2016-05-10 | Thync, Inc. | Methods for attaching and wearing a neurostimulator |
| AU2015271774B2 (en) | 2014-06-02 | 2020-04-16 | Cala Health, Inc. | Systems and methods for peripheral nerve stimulation to treat tremor |
| EP3171928B1 (en) * | 2014-07-25 | 2020-02-26 | Oculeve, Inc. | Stimulation patterns for treating dry eye |
| US12053630B2 (en) | 2014-08-17 | 2024-08-06 | Coloplast A/S | Implantable pulse generator with automatic jump-start |
| WO2016028608A1 (en) | 2014-08-17 | 2016-02-25 | Nine Continents Medical, Inc. | Miniature implatable neurostimulator system for sciatic nerves and their branches |
| EP3183028A4 (en) | 2014-08-21 | 2018-05-02 | The Regents of the University of California | Regulation of autonomic control of bladder voiding after a complete spinal cord injury |
| US9925376B2 (en) | 2014-08-27 | 2018-03-27 | Aleva Neurotherapeutics | Treatment of autoimmune diseases with deep brain stimulation |
| US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
| US10773074B2 (en) | 2014-08-27 | 2020-09-15 | The Regents Of The University Of California | Multi-electrode array for spinal cord epidural stimulation |
| US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
| WO2016036002A1 (ko) * | 2014-09-03 | 2016-03-10 | (주)와이브레인 | 경두개 전류 자극(tcs) 장치 |
| MA39415A (fr) * | 2014-09-17 | 2016-03-24 | Dart Neuroscience Cayman Ltd | Inhibiteurs de mao-b et rééducation |
| MX2017005204A (es) | 2014-10-22 | 2017-12-14 | Oculeve Inc | Dispositivos y métodos de estimulación para tratar el ojo seco. |
| CA2965514A1 (en) | 2014-10-22 | 2016-04-28 | Oculeve, Inc. | Contact lens for increasing tear production |
| US9364657B2 (en) | 2014-10-31 | 2016-06-14 | Ensilver Canada | Cuff unit for a functional electrical stimulation system |
| US9981127B2 (en) | 2014-12-03 | 2018-05-29 | Neurohabilitation Corporation | Systems and methods for providing non-invasive neurorehabilitation of a patient |
| USD751722S1 (en) | 2014-12-03 | 2016-03-15 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD750794S1 (en) | 2014-12-03 | 2016-03-01 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| US9072889B1 (en) | 2014-12-03 | 2015-07-07 | Neurohabilitation Corporation | Systems for providing non-invasive neurorehabilitation of a patient |
| US9789306B2 (en) | 2014-12-03 | 2017-10-17 | Neurohabilitation Corporation | Systems and methods for providing non-invasive neurorehabilitation of a patient |
| US9227051B1 (en) | 2014-12-03 | 2016-01-05 | Neurohabilitation Corporation | Devices for delivering non-invasive neuromodulation to a patient |
| USD752236S1 (en) | 2014-12-03 | 2016-03-22 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| US9993640B2 (en) | 2014-12-03 | 2018-06-12 | Neurohabilitation Corporation | Devices for delivering non-invasive neuromodulation to a patient |
| USD753316S1 (en) | 2014-12-03 | 2016-04-05 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD751213S1 (en) | 2014-12-03 | 2016-03-08 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD750268S1 (en) | 2014-12-03 | 2016-02-23 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| US9283377B1 (en) | 2014-12-03 | 2016-03-15 | Neurohabilitation Corporation | Devices for delivering non-invasive neuromodulation to a patient |
| USD749746S1 (en) | 2014-12-03 | 2016-02-16 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| US9415209B2 (en) | 2014-12-03 | 2016-08-16 | Neurohabilitation Corporation | Methods of manufacturing devices for the neurorehabilitation of a patient |
| USD753315S1 (en) | 2014-12-03 | 2016-04-05 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD750265S1 (en) | 2014-12-03 | 2016-02-23 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| US9415210B2 (en) | 2014-12-03 | 2016-08-16 | Neurohabilitation Corporation | Methods of manufacturing devices for the neurorehabilitation of a patient |
| US9272133B1 (en) | 2014-12-03 | 2016-03-01 | Neurohabilitation Corporation | Methods of manufacturing devices for the neurorehabilitation of a patient |
| USD750266S1 (en) | 2014-12-03 | 2016-02-23 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD760397S1 (en) | 2014-12-03 | 2016-06-28 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD750267S1 (en) | 2014-12-03 | 2016-02-23 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD750264S1 (en) | 2014-12-03 | 2016-02-23 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| US9616222B2 (en) | 2014-12-03 | 2017-04-11 | Neurohabilitation Corporation | Systems for providing non-invasive neurorehabilitation of a patient |
| USD751214S1 (en) | 2014-12-03 | 2016-03-08 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| USD759830S1 (en) | 2014-12-03 | 2016-06-21 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| US9656060B2 (en) | 2014-12-03 | 2017-05-23 | Neurohabilitation Corporation | Methods of manufacturing devices for the neurorehabilitation of a patient |
| USD752766S1 (en) | 2014-12-03 | 2016-03-29 | Neurohabilitation Corporation | Non-invasive neurostimulation device |
| CN107427663A (zh) | 2015-01-04 | 2017-12-01 | 赛威医疗公司 | 用于外耳的经皮刺激的方法和装置 |
| US11534608B2 (en) | 2015-01-04 | 2022-12-27 | Ist, Llc | Methods and apparatuses for transdermal stimulation of the outer ear |
| US10258788B2 (en) | 2015-01-05 | 2019-04-16 | Thync Global, Inc. | Electrodes having surface exclusions |
| MX2017009822A (es) | 2015-02-02 | 2018-03-14 | Novintum Medical Tech Gmbh | Aparato de estimulacion electrica venosa y sus metodos y usos. |
| US10668281B2 (en) * | 2015-03-13 | 2020-06-02 | Tokai University Educational System | Spinal cord stimulation device for gait training |
| KR102427652B1 (ko) | 2015-03-30 | 2022-08-01 | 세팔리 테크놀로지 에스피알엘 | 삼차 신경의 경피 전기 자극을 위한 장치 |
| EP3302682A1 (en) | 2015-05-29 | 2018-04-11 | Cerevast Medical Inc. | Methods and apparatuses for transdermal electrical stimulation |
| HK1246714A1 (zh) | 2015-06-01 | 2018-09-14 | 赛威医疗公司 | 用於神经调节的装置和方法 |
| KR20180021776A (ko) | 2015-06-04 | 2018-03-05 | 인빅타 메디컬 인코포레이티드 | 하지 불안 증후군을 치료하는 방법 및 장치 |
| EP4342516A3 (en) | 2015-06-10 | 2024-07-10 | Cala Health, Inc. | Systems and methods for peripheral nerve stimulation to treat tremor with detachable therapy and monitoring units |
| US10143397B2 (en) | 2015-06-15 | 2018-12-04 | Edward Lafe Altshuler | Electrode holding device |
| EP3106202B1 (en) * | 2015-06-18 | 2019-08-07 | Taipei Medical University | Transcranial burst electrostimulation apparatus |
| US10232172B1 (en) * | 2015-08-25 | 2019-03-19 | Neurological Fitness Equipment and Education LLC | System and methods to track and increase muscle efficiency |
| WO2017035512A1 (en) | 2015-08-26 | 2017-03-02 | The Regents Of The University Of California | Concerted use of noninvasive neuromodulation device with exoskeleton to enable voluntary movement and greater muscle activation when stepping in a chronically paralyzed subject |
| WO2017053847A1 (en) | 2015-09-23 | 2017-03-30 | Cala Health, Inc. | Systems and methods for peripheral nerve stimulation in the finger or hand to treat hand tremors |
| AU2016335931B2 (en) | 2015-10-06 | 2019-06-27 | Case Western Reserve University | High-charge capacity electrodes to deliver direct current nerve conduction block |
| US11318310B1 (en) | 2015-10-26 | 2022-05-03 | Nevro Corp. | Neuromodulation for altering autonomic functions, and associated systems and methods |
| US11097122B2 (en) | 2015-11-04 | 2021-08-24 | The Regents Of The University Of California | Magnetic stimulation of the spinal cord to restore control of bladder and/or bowel |
| US10864373B2 (en) | 2015-12-15 | 2020-12-15 | Case Western Reserve University | Systems for treatment of a neurological disorder using electrical nerve conduction block |
| US9956405B2 (en) | 2015-12-18 | 2018-05-01 | Thyne Global, Inc. | Transdermal electrical stimulation at the neck to induce neuromodulation |
| WO2017106878A1 (en) | 2015-12-18 | 2017-06-22 | Thync Global, Inc. | Apparatuses and methods for transdermal electrical stimulation of nerves to modify or induce a cognitive state |
| JP6771154B2 (ja) * | 2016-01-07 | 2020-10-21 | パナソニックIpマネジメント株式会社 | 転倒リスク判定装置、転倒リスク判定装置の作動方法、およびコンピュータプログラム |
| US9770587B2 (en) * | 2016-01-13 | 2017-09-26 | Kessler Foundation, Inc. | Neuromuscular stimulation system and method |
| JP6952699B2 (ja) | 2016-01-21 | 2021-10-20 | カラ ヘルス, インコーポレイテッドCala Health, Inc. | 過活動膀胱に関連する疾患を治療するための末梢神経調節のためのシステム、方法およびデバイス |
| ES2876148T3 (es) | 2016-01-25 | 2021-11-12 | Nevro Corp | Tratamiento de la insuficiencia cardíaca congestiva con estimulación eléctrica y sistemas y métodos asociados |
| US10252048B2 (en) | 2016-02-19 | 2019-04-09 | Oculeve, Inc. | Nasal stimulation for rhinitis, nasal congestion, and ocular allergies |
| WO2017165530A1 (en) * | 2016-03-22 | 2017-09-28 | The General Hospital Corporation | Selective activation of cortex using bent micro-wires to magnetically stimulate neurons |
| UY36936A (es) * | 2016-03-31 | 2017-11-30 | Medecell S A | Proceso para establecer un protocolo de electroestimulación, y el respectivo equipo portátil de electroestimulación utilizando el referido protocolo |
| EP3452166A4 (en) | 2016-05-02 | 2019-12-18 | Oculeve, Inc. | INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS |
| US10646708B2 (en) | 2016-05-20 | 2020-05-12 | Thync Global, Inc. | Transdermal electrical stimulation at the neck |
| IL264116B2 (en) | 2016-07-08 | 2024-01-01 | Cala Health Inc | Systems and methods for stimulating n nerves with exactly n electrodes and improved dry electrodes |
| IL264904B2 (en) | 2016-08-25 | 2025-05-01 | Cala Health Inc | Systems and methods for treating cardiac dysfunction through peripheral nerve stimulation |
| US10806942B2 (en) | 2016-11-10 | 2020-10-20 | Qoravita LLC | System and method for applying a low frequency magnetic field to biological tissues |
| EP3541279B1 (en) | 2016-11-15 | 2023-09-06 | The Regents of the University of California | Apparatuses for improving peripheral nerve function |
| RU2019118600A (ru) | 2016-12-02 | 2021-01-11 | Окулив, Инк. | Аппарат и способ составления прогноза синдрома сухого глаза и рекомендаций по лечению |
| EP3565631B1 (en) | 2017-01-05 | 2024-04-24 | Noctrix Health, Inc. | Restless leg syndrome or overactive nerve treatment |
| WO2021067751A1 (en) | 2019-10-03 | 2021-04-08 | Noctrix Health, Inc. | Peripheral nerve stimulation for restless legs syndrome |
| US10821285B2 (en) | 2017-01-05 | 2020-11-03 | California Institute Of Technology | Dueling bandits algorithm for neuromodulation therapy |
| IT201700005161A1 (it) | 2017-01-18 | 2018-07-18 | Viktor S R L | Metodo ed apparecchiatura di elettrostimolazione |
| EP4473909A3 (en) | 2017-02-17 | 2025-01-29 | The University of British Columbia | Apparatus and methods for maintaining physiological functions |
| CA3058786A1 (en) | 2017-04-03 | 2018-10-11 | Cala Health, Inc. | Systems, methods and devices for peripheral neuromodulation for treating diseases related to overactive bladder |
| WO2018187237A1 (en) | 2017-04-03 | 2018-10-11 | Presidio Medical, Inc. | Systems and methods for direct current nerve conduction block |
| DE202018001803U1 (de) | 2017-05-19 | 2018-06-27 | Cefaly Technology Sprl | Externe Trigeminusnervenstimulation für die Akutbehandlung von Migräneattacken |
| WO2018217791A1 (en) | 2017-05-23 | 2018-11-29 | The Regents Of The University Of California | Accessing spinal networks to address sexual dysfunction |
| EP3974021B1 (en) | 2017-06-30 | 2023-06-14 | ONWARD Medical N.V. | A system for neuromodulation |
| WO2019050896A2 (en) * | 2017-09-05 | 2019-03-14 | University Of Florida Research Foundation, Inc. | STIMULATION OF NEURONES MOTORS OF SPINAL CORD BY ELECTRICAL SIGNALS |
| US12357828B2 (en) | 2017-12-05 | 2025-07-15 | Ecole Polytechnique Federale De Lausanne (Epfl) | System for planning and/or providing neuromodulation |
| US11992684B2 (en) | 2017-12-05 | 2024-05-28 | Ecole Polytechnique Federale De Lausanne (Epfl) | System for planning and/or providing neuromodulation |
| EP3740274A4 (en) | 2018-01-17 | 2021-10-27 | Cala Health, Inc. | SYSTEMS AND METHODS FOR TREATING INFLAMMATORY INTESTINAL DISEASE USING PERIPHERAL NERVE STIMULATION |
| CA3090776A1 (en) | 2018-02-09 | 2019-08-15 | Presidio Medical, Inc. | Systems and methods for cardiac conduction block |
| CA3091769A1 (en) * | 2018-02-20 | 2019-08-29 | Presidio Medical, Inc. | Methods and systems for nerve conduction block |
| US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
| AU2019236304B2 (en) | 2018-03-15 | 2024-08-01 | Avent Investment, Llc | System and method to percutaneously block painful sensations |
| WO2019209969A1 (en) | 2018-04-24 | 2019-10-31 | Thync Global, Inc. | Streamlined and pre-set neuromodulators |
| US10493272B1 (en) | 2018-06-01 | 2019-12-03 | Feinstein Patents, Llc | Inferential electrical stimulation device with targeting capabilities |
| US11752329B2 (en) | 2018-07-01 | 2023-09-12 | Presidio Medical, Inc. | Systems and methods for nerve conduction block |
| JP2021534877A (ja) | 2018-08-23 | 2021-12-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 神経根麻痺、馬尾症候群、及び上肢機能の回復のための非侵襲性脊髄刺激 |
| EP3870271A1 (en) * | 2018-10-25 | 2021-09-01 | Zeev Bomzon | Delivering alternating electric fields (e.g., ttfields) to a subject's spinal anatomy |
| EP3653260A1 (en) | 2018-11-13 | 2020-05-20 | GTX medical B.V. | Sensor in clothing of limbs or footwear |
| EP3653256B1 (en) | 2018-11-13 | 2022-03-30 | ONWARD Medical N.V. | Control system for movement reconstruction and/or restoration for a patient |
| US12465718B2 (en) | 2019-01-18 | 2025-11-11 | Ist, Llc | Methods and devices for modulation of integrated neural networks to influence composite sensory processes |
| US11590352B2 (en) | 2019-01-29 | 2023-02-28 | Nevro Corp. | Ramped therapeutic signals for modulating inhibitory interneurons, and associated systems and methods |
| EP3695878B1 (en) | 2019-02-12 | 2023-04-19 | ONWARD Medical N.V. | A system for neuromodulation |
| US11623091B2 (en) | 2019-02-13 | 2023-04-11 | Avent, Inc. | Portable electrical stimulation system and method |
| US12257069B2 (en) | 2019-03-28 | 2025-03-25 | Sunrise Sa | System comprising a sensing unit and a device for processing data relating to disturbances that may occur during the sleep of a subject |
| WO2020193778A1 (en) | 2019-03-28 | 2020-10-01 | Sunrise Sa | System comprising a sensing unit and a device for processing data relating to disturbances that may occur during the sleep of a subject |
| CA3141360C (en) | 2019-07-02 | 2022-10-04 | Jorge SERANI MOSTAZAL | Equipment to elicit frissons or aesthetic chills, through the multisensorial and multimodal stimulation; with the objective of relieving chronic pains and the method to use it |
| EP3996804A1 (en) * | 2019-07-11 | 2022-05-18 | The University of Nottingham | Non-invasive brain stimulation |
| US12251560B1 (en) | 2019-08-13 | 2025-03-18 | Cala Health, Inc. | Connection quality determination for wearable neurostimulation systems |
| CN110404164B (zh) * | 2019-08-29 | 2020-12-22 | 苏州大学 | 脊髓闭环性电刺激系统 |
| US11890468B1 (en) | 2019-10-03 | 2024-02-06 | Cala Health, Inc. | Neurostimulation systems with event pattern detection and classification |
| JP2022551604A (ja) | 2019-10-03 | 2022-12-12 | ノクトリックス ヘルス インコーポレイテッド | むずむず脚症候群のための末梢神経刺激 |
| US11491324B2 (en) | 2019-10-16 | 2022-11-08 | Invicta Medical, Inc. | Adjustable devices for treating sleep apnea, and associated systems and methods |
| US12318610B1 (en) | 2019-10-18 | 2025-06-03 | Enlighten Mobility Llc | Gait trainer with neuromodulation integration |
| WO2021102448A1 (en) | 2019-11-24 | 2021-05-27 | Presidio Medical, Inc. | Pulse generation and stimulation engine systems |
| JP2023502507A (ja) | 2019-11-24 | 2023-01-24 | プレシディオ・メディカル・インコーポレイテッド | 電極動作のための制御メカニズムとしての電流バイアス |
| EP3827875B1 (en) | 2019-11-27 | 2023-07-05 | ONWARD Medical N.V. | Neuromodulation system |
| DE19211698T1 (de) | 2019-11-27 | 2021-09-02 | Onward Medical B.V. | Neuromodulation system |
| CA3163727A1 (en) * | 2019-12-04 | 2021-06-10 | Hi-Dow Iphc, Inc. | Wireless electrical stimulation system |
| US11878167B2 (en) | 2020-05-04 | 2024-01-23 | Btl Healthcare Technologies A.S. | Device and method for unattended treatment of a patient |
| EP4146335B1 (en) | 2020-05-04 | 2024-11-13 | BTL Healthcare Technologies a.s. | Device for unattended treatment of a patient |
| GB202012880D0 (en) * | 2020-08-18 | 2020-09-30 | Sky Medical Tech Ltd | Treatment of ischemia |
| US11839759B2 (en) | 2020-09-21 | 2023-12-12 | Neuro20 Technologies Corp. | Systems and methods for managed training and rehabilitation via electrical stimulation |
| CA3193534A1 (en) * | 2020-10-01 | 2023-03-22 | Pierre MARTINOT | Wearable device for decreasing the respiratory effort of a sleeping subject |
| CA3200092A1 (en) | 2020-11-04 | 2022-05-12 | Invicta Medical, Inc. | Implantable electrodes with remote power delivery for treating sleep apnea, and associated systems and methods |
| US10981003B1 (en) * | 2020-12-01 | 2021-04-20 | Feinstein Patents, Llc | System and method employing interferential electrical stimulation following shoulder surgery |
| US11491330B2 (en) * | 2021-01-20 | 2022-11-08 | Heby, Llc | Wellness device using interference frequencies |
| US12186564B2 (en) | 2021-02-09 | 2025-01-07 | The Regents Of The University Of California | Methods and apparatuses for treating stroke using low-frequency stimulation |
| US20230133737A1 (en) * | 2021-11-01 | 2023-05-04 | Leonhardt Ventures Llc | Modulation of growth differentiation factor 10 (gdf10) |
| TWI833616B (zh) * | 2023-03-24 | 2024-02-21 | 台灣共振波研發股份有限公司 | 電刺激系統 |
| US12491363B2 (en) | 2023-03-24 | 2025-12-09 | Taiwan Resonant Waves Research Corp. | Electrical stimulation system and a method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10501157A (ja) * | 1994-06-03 | 1998-02-03 | パレルモ,フランシス,エックス. | 電子神経筋刺激装置 |
| WO2006019764A2 (en) * | 2004-07-15 | 2006-02-23 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3648708A (en) | 1969-06-23 | 1972-03-14 | Mehdi Haeri | Electrical therapeutic device |
| US3817254A (en) | 1972-05-08 | 1974-06-18 | Medtronic Inc | Transcutaneous stimulator and stimulation method |
| US3902502A (en) | 1974-09-13 | 1975-09-02 | Saul Liss | Apparatus for temporarily arresting arthritic pain |
| AT332528B (de) | 1974-10-18 | 1976-10-11 | Nemec Hans | Elektromedizinischer apparat |
| US4444205A (en) | 1980-05-31 | 1984-04-24 | University Of Strathclyde | Apparatus for assessing joint mobility |
| US4844075A (en) | 1984-01-09 | 1989-07-04 | Pain Suppression Labs, Inc. | Transcranial stimulation for the treatment of cerebral palsy |
| US4576171A (en) | 1984-02-08 | 1986-03-18 | Richard Key | Animal immobilizing apparatus and method |
| JPS62502383A (ja) | 1985-04-03 | 1987-09-17 | メディコンペックス ソシエテ アノニム | 電気式神経筋刺激装置 |
| US4895154A (en) | 1988-02-19 | 1990-01-23 | Staodynamics, Inc. | Electronic stimulating device for enhanced healing of soft tissue wounds |
| JPH02265571A (ja) | 1989-04-07 | 1990-10-30 | Omron Tateisi Electron Co | 低周波治療器 |
| US5132361A (en) * | 1991-01-24 | 1992-07-21 | General Electric Company | Copolymers prepared from polymers of ethylenically polymerizable cyclic ortho esters |
| US5190053A (en) | 1991-02-28 | 1993-03-02 | Jeffrey A. Meer, Revocable Living Trust | Method and apparatus for electrical sublingual stimulation |
| US5109847A (en) | 1991-05-21 | 1992-05-05 | E.P. Inc. | Non-intrusive analgesic neuroaugmentive apparatus and management system |
| US5851223A (en) | 1991-05-21 | 1998-12-22 | Medi Consultants, Inc. | Combination non-intrusive analgesic neuroaugmentive system and method triple-modulated gigatens with optional bipolar spike |
| US5540736A (en) | 1993-08-02 | 1996-07-30 | Haimovich; Yechiel | Transcranial electrostimulation apparatus having two electrode pairs and independent current generators |
| US6425852B1 (en) | 1994-11-28 | 2002-07-30 | Emory University | Apparatus and method for transcranial magnetic brain stimulation, including the treatment of depression and the localization and characterization of speech arrest |
| US6132361A (en) | 1994-11-28 | 2000-10-17 | Neotonus, Inc. | Transcranial brain stimulation |
| US7039468B2 (en) | 1995-10-27 | 2006-05-02 | Esd Limited Liability Company | Method and apparatus for treating oropharyngeal disorders with electrical stimulation |
| US5725564A (en) | 1995-10-27 | 1998-03-10 | Esd Limited Liability Company | Method and apparatus for treating dysphagia with electrical stimulation |
| US7280873B2 (en) | 1995-10-27 | 2007-10-09 | Esd, Llc | Treatment of oropharyngeal disorders by application of neuromuscular electrical stimulation |
| US5891185A (en) | 1995-10-27 | 1999-04-06 | Esd Limited Liability Company | Method and apparatus for treating oropharyngeal disorders with electrical stimulation |
| US6198970B1 (en) | 1995-10-27 | 2001-03-06 | Esd Limited Liability Company | Method and apparatus for treating oropharyngeal respiratory and oral motor neuromuscular disorders with electrical stimulation |
| US5755758A (en) | 1995-11-07 | 1998-05-26 | Medtronic, Inc. | Intramuscular stimulation lead with enhanced infection resistance |
| US6865423B2 (en) * | 1996-06-13 | 2005-03-08 | The Victoria University Of Manchester | Stimulation of muscles |
| US6058938A (en) | 1998-01-23 | 2000-05-09 | Medelec Limited | Intramuscular stimulation therapy using localized electrical stimulation |
| US6179804B1 (en) | 1999-08-18 | 2001-01-30 | Oxypatch, Llc | Treatment apparatus for wounds |
| US6567702B1 (en) | 1999-10-15 | 2003-05-20 | The Board Of Trustees Of The Leland Stanford Junior University | Eliciting analgesia by transcranial electrical stimulation |
| US6341237B1 (en) * | 1999-10-25 | 2002-01-22 | Arthur F. Hurtado | Device for administrating electro-muscle stimulation and method of use |
| US6418344B1 (en) | 2000-02-24 | 2002-07-09 | Electrocore Techniques, Llc | Method of treating psychiatric disorders by electrical stimulation within the orbitofrontal cerebral cortex |
| US6526318B1 (en) | 2000-06-16 | 2003-02-25 | Mehdi M. Ansarinia | Stimulation method for the sphenopalatine ganglia, sphenopalatine nerve, or vidian nerve for treatment of medical conditions |
| US7146217B2 (en) | 2000-07-13 | 2006-12-05 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a change in a neural-function of a patient |
| US6405079B1 (en) | 2000-09-22 | 2002-06-11 | Mehdi M. Ansarinia | Stimulation method for the dural venous sinuses and adjacent dura for treatment of medical conditions |
| DE60139411D1 (de) | 2000-10-26 | 2009-09-10 | Medtronic Inc | Gerät zur minimierung der wirkungen einer herzverletzung |
| US6484053B2 (en) | 2000-11-29 | 2002-11-19 | Pairash Thajchayapong | Method and apparatus for treating poor laryngeal-elevation disorder with sequential-high voltage electrical stimulation |
| US20020161416A1 (en) | 2001-04-26 | 2002-10-31 | Justine Huang | Nerves and muscle stimulator |
| US6904322B2 (en) | 2002-02-15 | 2005-06-07 | Kalaco Scientific, Inc. | Transcranial electrostimulation apparatus and method |
| US7151961B1 (en) | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
| AU2003283964B9 (en) | 2002-09-27 | 2009-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and devices for intramuscular stimulation of upper airway and swallowing muscle groups |
| WO2004045391A2 (en) | 2002-11-20 | 2004-06-03 | Musc Foundation For Research Development | Methods and systems for using transcranial magnetic stimulation and functional brain mapping for examining cortical sensitivity, brain communication, and effects of medication |
| US20060161219A1 (en) | 2003-11-20 | 2006-07-20 | Advanced Neuromodulation Systems, Inc. | Electrical stimulation system and method for stimulating multiple locations of target nerve tissue in the brain to treat multiple conditions in the body |
| US20060004422A1 (en) | 2004-03-11 | 2006-01-05 | Dirk De Ridder | Electrical stimulation system and method for stimulating tissue in the brain to treat a neurological condition |
| US7657316B2 (en) | 2005-02-25 | 2010-02-02 | Boston Scientific Neuromodulation Corporation | Methods and systems for stimulating a motor cortex of the brain to treat a medical condition |
| WO2007019569A2 (en) * | 2005-08-09 | 2007-02-15 | International Rehabilitative Sciences, Inc. | An apparatus for surface electrical stimulation and stabilization to treat disorders of the joints |
| US7660636B2 (en) | 2006-01-04 | 2010-02-09 | Accelerated Care Plus Corp. | Electrical stimulation device and method for the treatment of dysphagia |
| US7949403B2 (en) * | 2007-02-27 | 2011-05-24 | Accelerated Care Plus Corp. | Electrical stimulation device and method for the treatment of neurological disorders |
| US7769463B2 (en) * | 2007-06-19 | 2010-08-03 | Kalaco Scientific, Inc. | Multi-channel electrostimulation apparatus and method |
-
2007
- 2007-02-27 US US11/711,285 patent/US7949403B2/en active Active
-
2008
- 2008-02-27 EP EP08726178A patent/EP2114516A4/en not_active Withdrawn
- 2008-02-27 JP JP2009551717A patent/JP2010519003A/ja active Pending
- 2008-02-27 WO PCT/US2008/002601 patent/WO2008106174A1/en not_active Ceased
-
2011
- 2011-05-23 US US13/113,389 patent/US8738142B2/en active Active
-
2014
- 2014-04-14 US US14/252,273 patent/US9802039B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10501157A (ja) * | 1994-06-03 | 1998-02-03 | パレルモ,フランシス,エックス. | 電子神経筋刺激装置 |
| WO2006019764A2 (en) * | 2004-07-15 | 2006-02-23 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
| JP2008506464A (ja) * | 2004-07-15 | 2008-03-06 | ノーススター ニューロサイエンス インコーポレイテッド | 神経刺激効率及び/又は効力の強化又はそれに影響を及ぼすためのシステム及び方法 |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013517049A (ja) * | 2010-01-15 | 2013-05-16 | チク,エルエルシー | 足筋のプログラム可能電気刺激 |
| JP2013525017A (ja) * | 2010-04-28 | 2013-06-20 | メーガン メディカル,インコーポレーテッド | 感覚神経を刺激するシステム及び方法 |
| JP2019177141A (ja) * | 2011-03-10 | 2019-10-17 | エレクトロコア リミテッド ライアビリティ カンパニー | 非侵襲的容量性電気刺激のためのデバイスおよび方法、ならびに患者の頸部の迷走神経刺激のためのそれらの使用 |
| JP2017080490A (ja) * | 2011-03-10 | 2017-05-18 | エレクトロコア リミテッド ライアビリティ カンパニー | 非侵襲的容量性電気刺激のためのデバイスおよび方法、ならびに患者の頸部の迷走神経刺激のためのそれらの使用 |
| JP2013215514A (ja) * | 2012-04-12 | 2013-10-24 | Nihon Medix | 電気的刺激装置およびその電極装置 |
| JP2015525579A (ja) * | 2012-06-26 | 2015-09-07 | マインドテック・インコーポレイテッド | 機能的電気刺激治療のための方法 |
| JP7776591B2 (ja) | 2013-01-21 | 2025-11-26 | カラ ヘルス,インコーポレイテッド | 振戦を抑制する装置及び方法 |
| JP2022168040A (ja) * | 2013-01-21 | 2022-11-04 | カラ ヘルス,インコーポレイテッド | 振戦を抑制する装置及び方法 |
| JP2024149616A (ja) * | 2013-01-21 | 2024-10-18 | カラ ヘルス,インコーポレイテッド | 振戦を抑制する装置及び方法 |
| JP2014188015A (ja) * | 2013-03-26 | 2014-10-06 | Kensuke Yamakawa | 電気的刺激装置 |
| US9919153B2 (en) | 2013-03-26 | 2018-03-20 | Kensuke Yamakawa | Electric stimulator |
| US11123557B2 (en) | 2013-03-26 | 2021-09-21 | Kensuke Yamakawa | Electric stimulator |
| JP2017525495A (ja) * | 2014-08-26 | 2017-09-07 | アヴェント インコーポレイテッド | 選択的神経線維ブロック方法及びシステム |
| JP2018526142A (ja) * | 2015-09-08 | 2018-09-13 | ケース ウェスタン リザーブ ユニバーシティCase Western Reserve University | 経皮直流電流ブロックによる神経伝導変更システム及び方法 |
| JP2022009436A (ja) * | 2015-09-08 | 2022-01-14 | ケース ウェスタン リザーブ ユニバーシティ | 経皮直流電流ブロックによる神経伝導変更システム及び方法 |
| JP2022008274A (ja) * | 2016-03-24 | 2022-01-13 | ヴィヴォニクス・インコーポレーテッド | ヒト被験者の前庭活動を抑制するためのシステムおよび方法 |
| JP2018183481A (ja) * | 2017-04-27 | 2018-11-22 | 株式会社 Mtg | 筋肉電気刺激装置 |
| JP7152845B2 (ja) | 2017-04-27 | 2022-10-13 | 株式会社 Mtg | 筋肉電気刺激装置 |
| KR20190064205A (ko) * | 2017-11-30 | 2019-06-10 | 주식회사 싸이버메딕 | 실시간 뇌 활성도 변화에 따른 모니터링과 중추 및 말초 신경 복합자극을 통한 뇌신경 조절장치 |
| KR102050319B1 (ko) | 2017-11-30 | 2019-12-02 | 주식회사 싸이버메딕 | 실시간 뇌 활성도 변화에 따른 모니터링과 중추 및 말초 신경 복합자극을 통한 뇌신경 조절장치 |
| KR102100696B1 (ko) | 2017-11-30 | 2020-04-16 | 주식회사 싸이버메딕 | 중추신경 및 말초 신경에 대한 복합자극을 이용한 뇌신경 조절장치 |
| KR20190128129A (ko) * | 2017-11-30 | 2019-11-15 | 주식회사 싸이버메딕 | 실시간 뇌 활성도 변화에 따른 모니터링과 중추 및 말초 신경 복합자극을 통한 뇌신경 조절장치 |
| WO2019107768A1 (ko) * | 2017-11-30 | 2019-06-06 | 주식회사 싸이버메딕 | 실시간 뇌 활성도 변화에 따른 모니터링과 중추 및 말초 신경 복합자극을 통한 뇌신경 조절장치 |
| US11338136B2 (en) | 2017-11-30 | 2022-05-24 | Cybermedic Co., Ltd. | Cranial nerve control device using both of monitoring according to real-time brain activity change and combined central and peripheral nerve stimulation |
| JP2019103655A (ja) * | 2017-12-13 | 2019-06-27 | 日本電信電話株式会社 | 筋緊張制御装置、筋緊張制御方法およびプログラム |
| JP2023083291A (ja) * | 2018-10-15 | 2023-06-15 | ノボキュア ゲーエムベーハー | 脳全体にわたる高均一性での腫瘍治療電場(tt電場)の発生 |
| JP7536934B2 (ja) | 2018-10-15 | 2024-08-20 | ノボキュア ゲーエムベーハー | 脳全体にわたる高均一性での腫瘍治療電場(tt電場)の発生 |
| US12208275B2 (en) | 2018-10-15 | 2025-01-28 | Novocure Gmbh | Generating tumor treating fields (TTFields) with high uniformity throughout the brain |
| KR102717384B1 (ko) | 2019-11-29 | 2024-10-15 | (주)와이브레인 | 신경 조절 장치, 방법 및 프로그램 |
| KR20220017952A (ko) * | 2019-11-29 | 2022-02-14 | (주)와이브레인 | 환자의 신경에 전기적인 자극을 가하여 신경을 조절하는 장치, 방법 및 프로그램 |
| WO2021107649A3 (ko) * | 2019-11-29 | 2021-07-15 | (주)와이브레인 | 환자의 신경에 전기적인 자극을 가하여 신경을 조절하는 장치 및 그 방법 |
| JP2024515260A (ja) * | 2021-04-08 | 2024-04-08 | ノボキュア ゲーエムベーハー | 交流電場を用いて神経変性障害を処置する方法 |
| WO2024071669A1 (ko) * | 2022-09-29 | 2024-04-04 | 서울대학교산학협력단 | 뇌심부 자극 장치 및 이의 제어 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| US7949403B2 (en) | 2011-05-24 |
| EP2114516A4 (en) | 2010-06-23 |
| US20150290457A1 (en) | 2015-10-15 |
| WO2008106174A1 (en) | 2008-09-04 |
| US20110224753A1 (en) | 2011-09-15 |
| US20080208287A1 (en) | 2008-08-28 |
| US9802039B2 (en) | 2017-10-31 |
| US20160243354A9 (en) | 2016-08-25 |
| US8738142B2 (en) | 2014-05-27 |
| EP2114516A1 (en) | 2009-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9802039B2 (en) | Electrical stimulation device and method for the treatment of neurological disorders | |
| US8660651B2 (en) | Electrical stimulation method for treatment of peripheral neuropathy | |
| US7725193B1 (en) | Intramuscular stimulation therapy using surface-applied localized electrical stimulation | |
| Pieber et al. | Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. | |
| Schuhfried et al. | Non-invasive neuromuscular electrical stimulation in patients with central nervous system lesions: an educational review | |
| Kralj et al. | Enhancement of hemiplegic patient rehabilitation by means of functional electrical stimulation | |
| Carhart et al. | Epidural spinal-cord stimulation facilitates recovery of functional walking following incomplete spinal-cord injury | |
| WO2012177377A2 (en) | Apparatus and method for stabilizing, improving mobility, and controlling cartilage matrix degradation of weight-bearing articular joints | |
| Hesse | Rehabilitation of gait after stroke: evaluation, principles of therapy, novel treatment approaches, and assistive devices | |
| Moon et al. | The effects of functional electrical stimulation on muscle tone and stiffness of stroke patients | |
| Perry et al. | The Determinants of Muscle Action in the Hemiparetic Lower Extremity:(And Their Effect on the Examination Procedure) | |
| Gerasimenko et al. | Sensorimotor regulation of movements: novel strategies for the recovery of mobility | |
| EP3402565B1 (en) | Neuromuscular stimulation system | |
| Kanakis et al. | Electrical stimulation and motor function rehabilitation in spinal cord injury: a systematic review | |
| Vitenzon et al. | Functional electrostimulation of muscles as a method for restoring motor functions | |
| US20250339446A1 (en) | Testosterone replacement therapy in combination with neuromuscular stimulation | |
| Michalski et al. | Does the Self‐Myofascial Release Affect the Activity of Selected Lower Limb Muscles of Soccer Players? | |
| Liberson | Functional electrotherapy | |
| Deshmukh et al. | Application of transcutaneous electrical stimulation on lower limb acupoints as an important adjunctive tool in stroke rehabilitation program & its effects on spasticity and functional ability | |
| Lategan et al. | Electrical muscle stimulation (EMS) training of the hamstrings | |
| Oostra et al. | Use of electrical stimulation in brain injured patients: a case report | |
| RU2284198C1 (ru) | Способ лечения параличей и парезов | |
| Schultz | TNS—The New Current in Sportsmedicine | |
| Ayodele | Comparative efficacy of cycle-ergometry exercise and glucosamine sulphate iontophoresis in pain management of subjects with sub-acute knee osteoarthritis. | |
| Heffernan et al. | The Orthotic Effect of Functional Electrical Stimulation on Reactive Stepping for People With Incomplete Spinal Cord Injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120925 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121221 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130528 |